Merck Appoints Maya Martinez-Davis as Global Head of Oncology
Merck KGaA
In her new role leading the Global Oncology Franchise, Martinez-Davis’ responsibilities will include defining integrated global oncology strategies, and delivery of therapeutic launches, starting with Avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for Avelumab is expected in 2017.
Prior to joining Merck, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.
Martinez-Davis assumes the role of her predecessor, Andrew Schiermeier.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.